

Subject Index, 1987

Vol. 37, Nos. 1-6

A

Adrenal gland cancer

(See also, Adrenocortical carcinoma)
Imaging in, 156, 158-160

Adrenocortical carcinoma, 348-365

Antihormonal therapy, 361-363
Chemotherapy, 357-363
Classification and staging, 348-349
Embolization, 361
Incidence, 348
Localization and staging, 352-353
Pathogenesis, 348
Presentation and diagnosis, 350-352
Radiation therapy, 361
Surgical treatment, 354-357
Survival rates for, 363

Alcohol

Risk factor in oropharyngeal cancer, 53-54

Announcements

American Cancer Society research in psychosocial and behavioral aspects of cancer, 77
Audrey Meyer Mars International Fellowships in Clinical Oncology, 377
Sexuality and the Patient with Cancer: Two New Booklets from the American Cancer Society, 333

B

Bladder cancer

Incidence of, 5, 12
Mortality of, 7, 11, 13
Survival rates for, 3-4

Bone cancer

Imaging in, 239-245
(See also, Imaging in cancer, bone)
Incidence of, 12
Mortality of, 7, 13
Survival rates for, 19

Bone marrow transplantation, 291-301

For aplastic anemia, 297-298
Autologous, 299
For cancer, 294-296
(See also, Leukemias and Lymphomas)
Complications of, 298-299
Economic and psychosocial implications, 299-300
Marrow aspirations, 292
The marrow donor, 292-293

Preparative regimens, 292, 294
For severe combined immunologic deficiency, 296
For thalassemia, 298
Types of disease amenable to, 291-292

Brain and central nervous system cancers

Imaging in, 225-232, 236-237
Incidence of, 12
Mortality of, 7, 13
Survival rates for, 3, 19

Breast cancer, 133-150, 246-251, 258-290

(See also, Breast Cancer Detection Demonstration Project)
Association with Klinefelter's syndrome, 246-251
Imaging in, 133-150
(See also, Imaging in cancer, breast; and Mammography)
Incidence of, 2, 5, 12, 14, 33
Male, association with Klinefelter's syndrome, 246-251
Mammography for control of, 33-48, 138, 372-375 (letters)
Mortality of, 2, 7, 10, 13, 15, 17, 33-35
Screening policies, 263, 266
Survival rates for, 3-4, 33, 258-259, 261-262, 264-266, 268-289

Breast Cancer Detection Demonstration Project (BCDDP), survival experience in, 258-290

Lead-time and length-time bias, 266
Materials, 266-267
Method, 267-272
Results, 260-262, 264-265, 268-289
Screening policies, 263, 266

C

Cancer clusters, 20-25

And environmental factors, 22-23
And leukemias, 20-21
And lymphomas, 20-21
And rare cancers, 21-22
Reporting a cluster, 23
Role of the clinician, 23
In uncommon age groups, 21-22

Cancer control

Prevention of cancer of the oral cavity and pharynx, 49-62
Using mammography for breast, 33-48, 138, 372-375 (letters)
Using flexible sigmoidoscopy for colorectal, 26-30

Chemotherapy, 93-105

Cancers with complete or partial remissions or minor responses to, 95
And curable cancers, 93-94
Listing of cancer chemotherapeutic agents, 98-103

Subject Index, 1987

Vol. 37, Nos. 1-6

A

Adrenal gland cancer

(See also, Adrenocortical carcinoma)
Imaging in, 156, 158-160

Adrenocortical carcinoma, 348-365

Antihormonal therapy, 361-363
Chemotherapy, 357-363
Classification and staging, 348-349
Embolization, 361
Incidence, 348
Localization and staging, 352-353
Pathogenesis, 348
Presentation and diagnosis, 350-352
Radiation therapy, 361
Surgical treatment, 354-357
Survival rates for, 363

Alcohol

Risk factor in oropharyngeal cancer, 53-54

Announcements

American Cancer Society research in psychosocial and behavioral aspects of cancer, 77
Audrey Meyer Mars International Fellowships in Clinical Oncology, 377
Sexuality and the Patient with Cancer: Two New Booklets from the American Cancer Society, 333

B

Bladder cancer

Incidence of, 5, 12
Mortality of, 7, 11, 13
Survival rates for, 3-4

Bone cancer

Imaging in, 239-245
(See also, Imaging in cancer, bone)
Incidence of, 12
Mortality of, 7, 13
Survival rates for, 19

Bone marrow transplantation, 291-301

For aplastic anemia, 297-298
Autologous, 299
For cancer, 294-296
(See also, Leukemias and Lymphomas)
Complications of, 298-299
Economic and psychosocial implications, 299-300
Marrow aspirations, 292
The marrow donor, 292-293

Preparative regimens, 292, 294
For severe combined immunologic deficiency, 296
For thalassemia, 298
Types of disease amenable to, 291-292

Brain and central nervous system cancers

Imaging in, 225-232, 236-237
Incidence of, 12
Mortality of, 7, 13
Survival rates for, 3, 19

Breast cancer, 133-150, 246-251, 258-290

(See also, Breast Cancer Detection Demonstration Project)
Association with Klinefelter's syndrome, 246-251
Imaging in, 133-150
(See also, Imaging in cancer, breast; and Mammography)
Incidence of, 2, 5, 12, 14, 33
Male, association with Klinefelter's syndrome, 246-251
Mammography for control of, 33-48, 138, 372-375 (letters)
Mortality of, 2, 7, 10, 13, 15, 17, 33-35
Screening policies, 263, 266
Survival rates for, 3-4, 33, 258-259, 261-262, 264-266, 268-289

Breast Cancer Detection Demonstration Project (BCDDP), survival experience in, 258-290

Lead-time and length-time bias, 266
Materials, 266-267
Method, 267-272
Results, 260-262, 264-265, 268-289
Screening policies, 263, 266

C

Cancer clusters, 20-25

And environmental factors, 22-23
And leukemias, 20-21
And lymphomas, 20-21
And rare cancers, 21-22
Reporting a cluster, 23
Role of the clinician, 23
In uncommon age groups, 21-22

Cancer control

Prevention of cancer of the oral cavity and pharynx, 49-62
Using mammography for breast, 33-48, 138, 372-375 (letters)
Using flexible sigmoidoscopy for colorectal, 26-30

Chemotherapy, 93-105

Cancers with complete or partial remissions or minor responses to, 95
And curable cancers, 93-94
Listing of cancer chemotherapeutic agents, 98-103

Mechanism of action of anticancer drugs, 97
New anticancer drugs, 93, 96, 104-105
For ovarian cancer, 252-253 (letters)

Childhood

Leading causes of death in, 18
Survival rates by site of cancer in, 19

Clinical trials

Ethical dilemma of Phase I, 256 (letters)
Knowledge of ongoing trials through the Physician Data Query (PDQ), 186-188

Clusters (Cancer), 20-25

(See Cancer clusters)

Colorectal cancer

Computed tomography staging of colonic tumors, 171
Detection by sigmoidoscopy, 26-28
And evaluation of training of non-endoscopists in flexible sigmoidoscopy, 26-30
Imaging in, 166-168, 172
(See also, Imaging in cancer, gastrointestinal tract)
Incidence of, 2, 5, 12, 14
Mortality of, 2, 7, 10-11, 13, 15-16, 28
Survival rates for, 3-4, 27-28

Condylomata and squamous cell carcinoma precursors of the lower female genital tract, 334-347

Laser treatment of, 334-347

Connective tissue cancer

Incidence of, 12
Mortality of, 7, 13

D

Dental trauma and oral sepsis

Risk factors in oropharyngeal cancer, 55-56

Depression in the cancer patient, 366-371

Diagnosis of, 367
Prevalence of, 366-367
Response to crisis, 366
Treatment of, 367-371
Benzodiazepines, 371
Lithium carbonate, 368
Monoamine oxidase inhibitors, 368
Psychostimulants, 368-371
Psychotherapy, supportive, 367
Second-generation antidepressants, 368
Tricyclic antidepressants, 367-368

E

Ear cancer, 78-87

Diagnosis of, 79, 81
Pathology of, 79-85
Treatment of, 81-86

Esophageal cancer

Computed tomography staging of esophageal carcinoma, 169
Imaging in, 166-169, 172
(See also, Imaging in cancer, gastrointestinal tract)
Incidence of, 5, 12
Mortality of, 11, 13
Survival rates for, 3-4

Ethics and cancer, 63-64 (letters)

Eye cancer

Incidence of, 12
Mortality of, 13
Retinoblastoma, 19

F

Feedback, 63-64, 126-128, 252-256, 372-377

Ethics and cancer, 63-64
Mammography, 372-375
Ovarian cancer, 252-255
Pain, 375-377
Phase I clinical trials, 256
Questionable cancer treatments, 126-128
Smokeless tobacco, 126

Fungi

Risk factors in oropharyngeal cancer, 56

G

Gallbladder and bile duct cancers

Imaging in, 177-178, 180

Genital tract cancer, female

(See specific sites, under Laser treatment)

H

Head and neck cancers

Imaging in, 232-236

Hypercalcemia associated with cancer, 302-308

Clinical presentation, 304
Diagnostic evaluation, 304
Pathophysiology, 302-305
Therapy, 304-308

Hypoglycemia associated with cancer,
314-317

- Clinical presentation, 316
- Diagnostic evaluation, 316-317
- Pathophysiology, 316
- Therapy, 317

Hyponatremia associated with cancer,
309-315

- Clinical presentation, 310-314
- Diagnostic evaluation, 313-315
- Etiology, 309-311
- Pathophysiology, 310, 312
- Therapy, 315

Imaging in cancer, 130-185, 194-245

- (See also, specific sites)
- In adrenal gland tumors, 156, 158-160
(See also, Adrenal gland cancer)
- In bone cancer, 239-245
- In breast cancer, 133-150
- In central nervous system and spinal cord tumors, 225-232, 236-237
- In gastrointestinal system tumors, 165-185
(See also, Gallbladder and Bile Duct; Liver; and Pancreatic Cancers)
- In gastrointestinal tract cancer, 166-169, 171-172
- In head and neck tumors, 232-238
- Imaging modalities, 165-166
- In kidney tumors, 151-157
(See also, Kidney cancer)
- In lung cancer, 194-204, 206-210
- In lymphomas, 211-217
(See also, Lymphomas, imaging in mediastinal)
- In mediastinal tumors, 211-224
- In metastatic disease, 205, 209-210
- In pharyngeal cancer, 232-234, 236
- In pleural cancers, 201, 204-205, 209-210
- In retroperitoneal tumors, 160-162

K

Kidney cancer

- Imaging in, 151-157
- Incidence of, 12
- Mortality of, 13
- Survival rates for, 3, 19

Klinefelter's syndrome, association with breast cancer, 246-251

L

Laryngeal cancer

- Incidence of, 12

- Mortality of, 13
- Survival rates for, 3

Laser treatment, for condylomata and squamous cell carcinoma precursors of the lower female genital tract, 334-347

- Excision procedures, 339-340
- Follow-up, 340-341
- Hazards, 335
- Principles and bioeffects of laser energy, 334-335
- Recurrent disease, 346
- Side effects, 346
- Treatment procedures, 335-341
- Treatment results, 341-346

Leukemias

- Bone marrow transplantation for, 294-296
- And cancer clusters, 20-21
- Incidence of, 2, 12, 14
- Mortality of, 2, 7, 10-11, 13, 15, 17
- Survival rates for, 3, 19, 294-297

Liver cancer

- Imaging in, 175-179
- Incidence of, 5, 12
- Mortality of, 10-11, 13
- Survival rates for, 3-4

Lung cancer

- Imaging in, 194-204, 206-210
(See also, Imaging in cancer, lung)
- Incidence of, 2, 5, 12, 14
- Mortality of, 2, 7, 10-11, 13, 15, 17
- Survival rates for, 3-4

Lymphomas

- Bone marrow transplantation for, 296
- And cancer clusters, 20-21
- Imaging in mediastinal, 211-217
- Incidence of, 2, 12
- Mortality of, 2, 7, 13
- Survival rates for, 3, 19

M

Mammography, 33-48, 133-146,
372-375 (letters)

- Benefits of, 33-35, 138
- For breast cancer control, 33-48, 138
- In the Breast Cancer Detection Demonstration Project (BCDDP), 258-259, 263, 265-270, 278, 282-289
- Deterrents to the use of, 39-43
- Film mammography, 133-135
- Guidelines for use, 35, 138, 142-143
- Patterns of use, 35-37
- Prospects for increasing the use of, 42, 44-46
- Referral patterns, 36, 38-39

- Xeromammography, 134-146
 - Dedicated mammography equipment, 136-138, 140
 - Evaluation of the contralateral breast, 142, 144
 - Galactography, 144, 146
 - Historical background, 134-135
 - Imaging principles—edge enhancement, 135-136
 - Liquid development, 136-137, 139
 - Magnification, 137-138
 - Mammary calcifications, 140
 - Parenchymal asymmetries, 140, 142, 145
 - Pneumocystography, 144, 147
 - Preoperative needle localization of nonpalpable lesions, 142
 - Radiation exposure dose, 138-139, 141
 - Radiographic change, 138, 140, 142
 - And radiotherapy, 144-146
 - Selection of patients for conservative treatment, 146

- Mediastinal tumors**, imaging in, 211-224
 - (See also, Lymphomas, Imaging in)
 - Benign tumors, 219, 222-223
 - Germ cell tumors, 216-217, 220
 - Giant mediastinal lymph node hyperplasia, 221, 223
 - Hemangiopericytomas, 222-223
 - Intrathoracic lymph node metastases (from extrathoracic tumors), 221-222
 - Intrathoracic thyroid masses, 217-218, 220-221
 - Lipomatosis, 223
 - Liposarcomas, 221, 223
 - Malignant fibrous histiocytoma, 219, 222
 - Thymic tumors, 217-219

Metabolic oncologic emergencies, 302-320

- (See Hypercalcemia; Hypoglycemia; Hyponatremia; and Uric Acid Nephropathy)

Mortality

- Leading causes of death, 6, 8-9
- In children, 18

Multiple myeloma

- Incidence of, 12
- Mortality of, 13
- Survival rates for, 3

N

Nutrition

- And cancer prevention (letters), 126-127
- Risk factor in oropharyngeal cancer, 54-55

O

Occupational risk factors

- In oropharyngeal cancer, 55

Opinion, 31-32

- Abusing children by smoking, 31-32

Oral cancer, 49-62

- (See also, Pharyngeal cancer)
- Imaging in, 232-236
- Incidence of, 2, 12, 14, 49
- Mortality of, 2, 13, 15, 16, 49
- Prevention of, 49-62
- Risk factors, 49-56
 - Actinic radiation, 55
 - Alcohol, 53-54
 - Dental trauma and oral sepsis, 55-56
 - Geographic location, 49-57
 - Ionizing radiation, 55
 - Nutrition, 54-55
 - Occupational, 55
 - Reverse smoking, 52
 - Snuff dipping, 51-52
 - Syphilis, viruses, and fungi, 56
 - Tobacco and betel-nut quid chewing, 52-53
 - Tobacco smoking, 50-51, 54
- Survival rates for, 3

Ovarian cancer

- Chemotherapy for, 252-253 (letters)
- Incidence of, 2, 5, 12
- Mortality of, 2, 7, 10, 13
- Radiation therapy for, 254-255 (letters)
- Survival rates for, 3-4
- Workup for, 253-254 (letters)

P

Pain, 375-377 (letters)

Pancreatic cancer

- Imaging in, 168, 170-171, 173-174
- Incidence of, 2, 12, 14
- Mortality of, 2, 7, 10-11, 13, 15
- Survival rates for, 3

Pharyngeal cancer, 49-62

- Imaging in, 232-234, 236
- Incidence of, 12, 49
- Mortality of, 13, 49
- Prevention of, 49-62
- Risk factors, 49-56
 - (See also, Oral cancer)
- Survival rates for, 3

- Physician Data Query (PDQ)**, a clinically oriented computer data base for information on cancer treatment, 186-192
 - Availability of, 190-192

Cancer information file, 186-189
Future plans, 192
Keeping the data current, 188, 191
Ongoing clinical trials file, 186-188
Organization directory, 186-190
Physician directory, 186-189

Prevention of cancer
(See Cancer control)

Prostate cancer
Incidence of, 2, 5, 12, 14
Mortality of, 2, 7, 11, 13, 15, 17
Survival rates for, 3-4

Psychological aspects of cancer, 322-333,
366-371
(See also, Depression; and Sexual
response)

R

Radiation
Radiation risks of mammography, 39-40,
138-139, 141
Risk factor in oropharyngeal cancer, 55

Retropertitoneal cancer
Imaging in, 160-162

S

Sexual response and cancer, 120-122,
322-333
Changes in body image or self-esteem,
325
Emotional responses to the diagnosis,
323-324
Loss of sexual drive, 324
Operations that require stoma
construction, pelvic exenteration,
cystectomy, and abdominoperineal
resection, 331-332
Problems for female sexuality, 120-122,
325-327
Problems for male sexuality, 120-121,
327-331
Taking a sexual history and continuing
discussion of sex, 322-323

Sigmoidoscopy, flexible, 26-30
Compared with rigid sigmoidoscopy,
26-28
Evaluation of training of non-endoscopists
in, 26-30
Use in detection and diagnosis of
colorectal cancer, 26-28

Skin cancer
Incidence of, 2, 5, 12
Mortality of, 2, 7, 13
Survival rates for, 3-4

Small intestine cancer
Incidence of, 12
Mortality of, 13

Smokeless tobacco, 126 (letter)
Risk factor in oropharyngeal cancer, 51-53

Smoking, 31-32
Abusing children by, 31-32 (opinion)
Fetal injury caused by, 31-32 (opinion)
Risk factor in oropharyngeal cancer,
50-52, 54

Soft tissue cancer
Survival rates for, 19

Soft tissue tumors, benign, 66-76
With abnormal mitotic figures, 74-75
Adipose tissue tumors, 68, 71-73
Borderline or atypical tumors, 74-75
Classification and natural history, 66-76
Extraskelatal bone tumors, 70, 73, 75
Fibrous tissue tumors, 69, 71-72
Incidence of, 66
Miscellaneous tumors, 70, 75
Muscle tumors, 67, 72-73
Tendosynovial tissue tumors, 67, 71-72
Tumors of peripheral nerves, 70, 73, 75
Tumors of vessels, 69, 73
Undifferentiated connective tissue tumors,
67, 71

**Squamous cell carcinoma precursors and
condylomata of the lower female genital
tract**, 334-347
Laser treatment of, 334-347

Statistics, cancer, 2-19
(See also, Childhood; and specific sites)

Stomach cancer
Computed tomography staging of gastric
adenocarcinoma, 169
Imaging in, 166-169, 172
(See also, Imaging in cancer,
gastrointestinal tract)
Incidence of, 5, 12, 14
Mortality of, 7, 10-11, 13, 15, 17
Survival rates for, 3-4

Sympathetic nervous system cancer
Survival rates for, 19

Syphilis
Risk factor in oropharyngeal cancer, 56

T

Testicular cancer

- Incidence of, 5, 12
- Mortality of, 13
- Survival rates for, 3-4

Thyroid cancer

- Incidence of, 12
- Mortality of, 13
- Survival rates for, 3

Treatment of cancer

- A computer data base for information on, 186-192
 - (See also, Physician Data Query [PDQ])
- Of ear cancer, 81-86
- Problems related to cancer and, 106-125
 - Anemia, 107
 - Bleeding due to thrombocytopenia, 107-108
 - Constipation, 108
 - Diarrhea, 109-110
 - Difficulty in swallowing, 110
 - Dry mouth, 110-111
 - Fatigue, 111-112
 - Hair loss, 112-113
 - Infection, 113-114
 - Itchy skin, 114-115
 - Loss of appetite, 115-117
 - Mouth and throat ulcers, 117-118
 - Nausea and vomiting, 118-119
 - Pain, 119; 375-377 (letters)
 - Respiratory problems, 119-120
 - Sexual and reproductive problems, 120-122, 322-333
 - Skin reactions, 122-124

- Taste alterations, 124
- Urinary tract problems, 124-125
- Questionable cancer treatments, 126-128 (letters)

Tumor board, 88-92

- Assessing benefits of, 90-91
- Legal issues, 91-92
- Objectives, 88-89
- Organizational structure, 89-90
- Role of in community hospitals, 88-92

U

Uric acid nephropathy associated with cancer, 308-309

- Clinical presentation and diagnostic evaluation, 308-309
- Pathophysiology, 308
- Therapy, 309

Urinary cancer

- (See also, Bladder cancer; and Kidney cancer)
- Incidence of, 2, 12
- Mortality of, 2, 13

Uterine cancer

- Incidence of, 2, 5, 12, 14
- Mortality of, 2, 7, 10, 13, 15, 17
- Survival rates for, 3-4

V

Viruses

- Risk factors in oropharyngeal cancer, 56

Author Index, 1987

Vol. 37, Nos. 1-6

Althausen AF, 322-333
Appleton M, 376 (letter)

Baden E, 49-62
Baldwin MP, 26-30
Barber HRK, 253-255 (letters)
Bragg DG, 131-132
Brennan MF, 348-365

Cahan WG, 31-32
Cnasen MH, 194-210
Crichlow RW, 246-251
Cummins RL, 26-30

Davidson AJ, 151-164
DeVita VT, Jr., 186-192
Dillon WP, 225-238
Dixon JA, 26-30
Dodd GD, 131-132, 374-375 (letter)

Edeiken J, 239-245
Ephraim R, 26-30
Evans DB, 246-251

Ferenczy A, 334-347
Foley KM, 376-377 (letters)
Fullerton JL, 64 (letter)

Garfinkel L, 20-25
Gelb SK, 258-290
Glasgow M, 322-333
Glick JH, 302-320
Glover DJ, 302-320
Greene P, 106-125
Gross GE, 88-92

Hajdu SI, 66-76
Halfin V, 322-333
Harnsberger HR, 225-238
Hartman DS, 151-164
Henney JE, 186-192
Hittle RE, 375 (letter)
Holland JC, 366-371
Howard J, 33-48, 373-374 (letter)
Hubbard SM, 186-192

Jarvis W, 127-128 (letters)
Jewett DL, 256 (letter)

Karasick D, 239-245
Kennemer CE, 256 (letter)
Krakoff IH, 93-105

Laura JE, 126 (letter)
LaVerda N, 258-290
Lewis JS, 78-87
Loeb V, Jr., 63 (letter)
Longley JD, 253-254 (letter)
Lubera JA, 2-19, 258-290

Miller CH, 26-30
Moore GE, 373 (letter)
Morrow A, 63-64 (letter)
Mueller HA, 253-254 (letter)

Ozols RF, 252-253 (letter)

Paulus DD, 133-150
Peschel RE, 254-255 (letter)
Primomo MP, 63 (letter)

Schapiro M, 26-30
Seidman H, 258-290
Siegel BS, 127 (letter)
Silverberg E, 2-19, 258-290
Stark P, 211-224

Talbott TM, 26-30
Taylor LH, 126-127 (letter)
Thomas ED, 291-301
Thompson WM, 165-185

Weissman GS, 26-30
Winawer SJ, 26-30
Wishik SM, 372-373 (letter)

Yasko JM, 106-125

